Methods for clinical monitoring of craniocerebral diseases based on electromagnetic field biodetection technology

Abstract

This invention belongs to the technical field of monitoring methods, specifically disclosing a method for clinical monitoring of craniocerebral diseases based on electromagnetic field biodetection technology. The method includes preparing four electrode pads, which are respectively fixed to the left and right sides of the patient's brain, the forehead, and the occipital region. The electrode pads are then connected to a monitor. Based on the detection data from the four electrode pads, the monitor obtains detection parameters at each time point: R1 represents the perturbation coefficient generated by the left and forehead electrode pads, R2 represents the perturbation coefficient generated by the right and forehead electrode pads, R3 represents the perturbation coefficient generated by the left and occipital region electrode pads, R4 represents the perturbation coefficient generated by the right and left sides electrode pads and the occipital region electrode pads, and R5 represents the perturbation coefficient generated by the left and right sides electrode pads or the perturbation coefficient of the entire brain. The method assesses the degree of edema, the presence of hemorrhage, or fluid accumulation. Using four electrodes positioned at different locations in the brain allows for targeted, three-dimensional, multi-parameter detection of lesions in different parts of the brain.

Description

Technical Field

[0001] This invention belongs to the field of monitoring methods, and particularly relates to a method for clinical monitoring of craniocerebral diseases based on electromagnetic field biodetection technology. Background Technology

[0002] Intracranial diseases such as stroke, cerebral hemorrhage, cerebral infarction, brain tumor, brain injury, encephalitis, intracranial infection, and epilepsy pose a great threat to human health. The treatment of intracranial diseases is very difficult, specifically due to their high incidence, high disability rate, and high mortality rate. Therefore, accurate monitoring of clinical treatment and implementation of different treatment plans according to different stages of disease development are crucial in the clinical treatment of intracranial diseases.

[0003] Electromagnetic field biodetection technology is a cutting-edge technology internationally, and its application in the detection of intracranial diseases is a significant future direction in the field of neurology. Due to its advantages, such as being non-invasive, digital, real-time, and portable, this technology can achieve safe and accurate results in the detection of intracranial diseases, and therefore has received considerable attention from the neurological community.

[0004] The current advancements in electromagnetic field biodetection technology worldwide have resulted in a relatively crude method for detecting intracranial diseases. This involves using detection parameters such as perturbation coefficients and bioimpedance coefficients to achieve a rough detection of the entire brain, and then determining a treatment plan based on the detection results.

[0005] The current method of using electromagnetic field biodetection technology for cranial examination involves placing an electrode on each side of the patient's brain to obtain the perturbation coefficient of the whole brain, and then determining the treatment plan based on the perturbation coefficient of the whole brain.

[0006] The above method can only obtain the perturbation coefficient of the whole brain, but cannot determine the specific location of the problem in the cranium. The accuracy of the test results is not high, which leads to an imperfect treatment plan. Summary of the Invention

[0007] The purpose of this invention is to provide a method for clinical monitoring of intracranial diseases based on electromagnetic field biodetection technology, in order to solve the problem that current detection methods are not perfect and the accuracy of detection results is not high.

[0008] To achieve the above objectives, the technical solution of the present invention is: a method for clinical monitoring of intracranial diseases based on electromagnetic field biodetection technology, comprising:

[0009] Prepare four electrode pads and fix them to the left and right sides of the patient's brain, the forehead and the back of the head, respectively. Connect the electrode pads to the monitor.

[0010] The monitor obtains detection parameters at each time point based on the detection data from the four electrode pads. The detection parameters include R1, R2, R3, R4, and R5, where R1 represents the perturbation coefficient generated by the electrode pads on the left side and forehead, R2 represents the perturbation coefficient generated by the electrode pads on the right side and forehead, R3 represents the perturbation coefficient generated by the electrode pads on the left side and back of the head, R4 represents the perturbation coefficient generated by the electrode pads on the left and right sides and back of the head, and R5 represents the perturbation coefficient generated by the electrode pads on the left and right sides or the perturbation coefficient of the whole brain. The monitor also generates a linear graph of the perturbation coefficient versus time for each detection parameter.

[0011] The edema, hematoma, and fluid accumulation are calculated based on the test parameters to determine the degree of edema, whether there is bleeding, or whether fluid accumulation has occurred.

[0012] Furthermore, the detection parameter is set to R. i Let i = 1, 2, 3, 4, 5; the total monitoring time is t; n time detection points are set sequentially within the time range of t, namely t1, t2, t3…tn, and tm represents any time monitoring point, where n ≥ m > 1; the judgment parameters are calculated based on the detection parameters, and the judgment parameters include R. ix MAX(R) ix ), R ixa R ixb ;in

[0013] R ix =R it(m-1) -R itm R it(m-1) R represents the value at time t(m-1). i Value, R itm R represents the value at time point tm. i Value; MAX(R) ix R represents the total monitoring time t. ix The maximum value;

[0014] R ixa =MAX{|R 1t1 -R 2t1 |,|R 1t2 -R 2t2 |,…,|R 1tn -R 2tn |}-MIN{|R 1t1 -R 2t1 |,|R 1t2 -R 2t2 |,…,|R 1tn -R 2tn |};

[0015] R ixb =MAX{|R 3t1 -R 4t1 |,|R3t2 -R 4t2 |,…,|R 3tn -R 4tn |}-MIN{|R 3t1 -R 4t1 |,|R 3t2 -R 4t2 |,…,|R 3tn -R 4tn |};

[0016] According to R ix R ixa Or R ixb Assess the degree of edema; based on MAX(R) ix ), R ixa Or R ixb 1. Determine the extent of bleeding or fluid accumulation.

[0017] Furthermore, the methods for assessing the degree of edema include the following three:

[0018] (a) 20 > R ix (i=1,2,3,4,5)≥10 indicates that the edema at this location is slightly aggravated;

[0019] 30>Rix R ix (i=1,2,3,4,5)≥20 indicates that the edema at this location is moderately aggravated;

[0020] R ix (i=1,2,3,4,5)≥30 indicates that the edema at this location is severely aggravated;

[0021] (ii) -20≤R ix (i = 1, 2, 3, 4, 5) < -10, indicating that the edema at this location has been slightly reduced;

[0022] -30≤Rix R ix (i=1,2,3,4,5)<-20, indicating that the edema at this location has been moderately reduced;

[0023] R ix (i=1,2,3,4,5)<-30, indicating that the edema at this location has been significantly reduced;

[0024] (iii) 24 > R ixa Or R ixb ≥12 indicates that the edema at that location has either slightly worsened or slightly improved;

[0025] 36>R ixa Or R ixb ≥24 indicates that the edema at this location has either worsened or improved moderately;

[0026] R ixaOr R ixb ≥36 indicates that the edema at that location has either significantly worsened or significantly lessened.

[0027] Furthermore, the methods for assessing bleeding or fluid accumulation include the following two:

[0028] (I) MAX(R) ix A value ≥15 indicates bleeding or fluid accumulation at that location;

[0029] (II) R ixa Or R ixb A score of ≥12 indicates bleeding or fluid accumulation at that location.

[0030] Furthermore, the total monitoring time t ≤ 20 min.

[0031] Furthermore, the electrode pad is a cranial detection sensor.

[0032] Furthermore, the monitor uses a non-invasive dynamic cerebral edema monitor.

[0033] Furthermore, a calculation module is used to calculate edema, hematoma, and fluid accumulation based on the detection parameters.

[0034] The beneficial effects of this technical solution are as follows: Using four electrodes positioned at different locations in the brain, it enables targeted, three-dimensional, multi-parameter detection of lesions in different brain regions. The computational module within this solution performs rapid and automatic calculations, helping doctors quickly assess changes in the condition of bleeding patients. Detailed Implementation

[0035] The following detailed description illustrates the specific implementation method:

[0036] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0037] A method for clinical monitoring of intracranial diseases based on electromagnetic field biodetection technology includes the following steps:

[0038] Step S1: Prepare four electrode pads (specifically, cranial detection sensors), and attach and fix them to the left and right sides of the patient's brain, the forehead, and the back of the head, respectively. Connect the electrode pads to the monitor.

[0039] Step S2: The monitor obtains the detection parameters at each time point based on the detection data from the four electrode pads. The detection parameters are set as R. i, i = 1, 2, 3, 4, 5, where R1 represents the perturbation coefficient generated by the electrode pads on the left side and forehead, R2 represents the perturbation coefficient generated by the electrode pads on the right side and forehead, R3 represents the perturbation coefficient generated by the electrode pads on the left side and occipital region, R4 represents the perturbation coefficient generated by the electrode pads on the left and right sides and occipital region, and R5 represents the perturbation coefficient generated by the electrode pads on the left and right sides or the perturbation coefficient of the whole brain; and generate a perturbation coefficient versus time linearity graph for each detection parameter;

[0040] Step S3: The calculation module calculates edema, hematoma, and fluid accumulation based on the detection parameters to obtain judgment parameters. These parameters are then used to determine the degree of edema and whether bleeding or fluid accumulation has occurred. The calculation module calculates the judgment parameters as follows:

[0041] Assuming the total monitoring time is t, t≤20min, n time monitoring points are sequentially set within the total monitoring time t, namely t1, t2, t3…tn, and tm represents any time monitoring point, n≥m>1; the judgment parameters are calculated based on the monitoring parameters, and the judgment parameters include R. ix MAX(R) ix ), R ixa R ixb ;in

[0042] R ix =R it(m-1) -R itm R it(m-1) R represents the value at time t(m-1). i Value, R itm R represents the value at time point tm. i Value; MAX(R) ix R represents the total monitoring time t. ix The maximum value;

[0043] R ixa =MAX{|R 1t1 -R 2t1 |,|R 1t2 -R 2t2 |,…,|R 1tn -R 2tn |}-MIN{|R 1t1 -R 2t1 |,|R 1t2 -R 2t2 |,…,|R 1tn -R 2tn |};

[0044] R ixb =MAX{|R 3t1 -R 4t1 |,|R 3t2 -R4t2 |,…,|R 3tn -R 4tn |}-MIN{|R 3t1 -R 4t1 |,|R 3t2 -R 4t2 |,…,|R 3tn -R 4tn |};

[0045] According to R ix R ixa Or R ixb Assess the degree of edema; based on MAX(R) ix ), R ixa Or R ixb 1. Determine the extent of bleeding or fluid accumulation, where MAX(R) ix R represents the total monitoring time t. ix The maximum value.

[0046] The following three methods are used to assess the degree of edema:

[0047] (a) 20 > R ix (i=1,2,3,4,5)≥10 indicates that the edema at this location is slightly aggravated;

[0048] 30>Rix R ix (i=1,2,3,4,5)≥20 indicates that the edema at this location is moderately aggravated;

[0049] R ix (i=1,2,3,4,5)≥30 indicates that the edema at this location is severely aggravated;

[0050] (ii) -20≤R ix (i = 1, 2, 3, 4, 5) < -10, indicating that the edema at this location has been slightly reduced;

[0051] -30≤Rix R ix (i=1,2,3,4,5)<-20, indicating that the edema at this location has been moderately reduced;

[0052] R ix (i=1,2,3,4,5)<-30, indicating that the edema at this location has been significantly reduced;

[0053] (iii) 24 > R ixa Or R ixb ≥12 indicates that the edema at that location has either slightly worsened or slightly improved;

[0054] 36>R ixa Or R ixb ≥24 indicates that the edema at this location has either worsened or improved moderately;

[0055] R ixa Or R ixb ≥36 indicates that the edema at that location has either significantly worsened or significantly lessened.

[0056] The methods for assessing bleeding or fluid accumulation include the following two:

[0057] (I) MAX(R) ix A value ≥15 indicates bleeding or fluid accumulation at that location;

[0058] (II) R ixa Or R ixb A score of ≥12 indicates bleeding or fluid accumulation at that location.

[0059] It should be noted that, in this document, relational terms such as "first" and "second" are used only to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, method, article, or apparatus.

[0060] The above descriptions are merely embodiments of the present invention. Commonly known structures and characteristics are not described in detail here. Those skilled in the art are aware of all common technical knowledge in the field prior to the application date or priority date, are aware of all existing technologies in that field, and have the ability to apply conventional experimental methods prior to that date. Those skilled in the art can, under the guidance of this application, improve and implement this solution in combination with their own capabilities. Some typical known structures or methods should not be obstacles for those skilled in the art to implement this application. It should be noted that those skilled in the art can make several modifications and improvements without departing from the structure of the present invention. These should also be considered within the scope of protection of the present invention, and will not affect the effectiveness of the implementation of the present invention or the practicality of the patent. The scope of protection claimed in this application should be determined by the content of its claims, and the specific embodiments described in the specification can be used to interpret the content of the claims.

Claims

1. A method for clinical monitoring of intracranial diseases based on electromagnetic field biodetection technology, characterized in that: include Prepare four electrode pads and fix them to the left and right sides of the patient's brain, the forehead and the back of the head, respectively. Connect the electrode pads to the monitor. The monitor obtains detection parameters at each time point based on the detection data from the four electrode pads. The detection parameters include R1, R2, R3, R4, and R5, where R1 represents the perturbation coefficient generated by the electrode pads on the left side and forehead, R2 represents the perturbation coefficient generated by the electrode pads on the right side and forehead, R3 represents the perturbation coefficient generated by the electrode pads on the left side and back of the head, R4 represents the perturbation coefficient generated by the electrode pads on the right side and back of the head, and R5 represents the perturbation coefficient generated by the electrode pads on the left and right sides or the perturbation coefficient of the whole brain; and generates a linear graph of the perturbation coefficient versus time for each detection parameter. Edema, hematoma, and fluid accumulation are calculated based on the detection parameters; the detection parameters are set as R. i Let i = 1, 2, 3, 4, 5; the total monitoring time is t; n time detection points are set sequentially within the time range of t, namely t1, t2, t3…tn, and tm represents any time monitoring point, where n ≥ m > 1; the judgment parameters are calculated based on the detection parameters, and the judgment parameters include R. ix MAX(R) ix ), R ixa R ixb ;in R ix =R it（m-1） -R itm R it（m-1） R represents the value at time t(m-1). i Value, R itm R represents the value at time point tm. i Value; MAX(R) ix R represents the total monitoring time t. ix The maximum value; R ixa =MAX{|R 1t1 -R 2t1 |,|R 1t2 -R 2t2 |,…,|R 1tn -R 2tn |}- MIN{|R 1t1 -R 2t1 |,|R 1t2 -R 2t2 |,…,|R 1tn -R 2tn |}; R ixb =MAX{|R 3t1 -R 4t1 |,|R 3t2 -R 4t2 |,…,|R 3tn -R 4tn |}- MIN{|R 3t1 -R 4t1 |,|R 3t2 -R 4t2 |,…,|R 3tn -R 4tn |}。 2. The method for clinical monitoring of intracranial diseases based on electromagnetic field biodetection technology according to claim 1, characterized in that: The total monitoring time t ≤ 20 min.

3. The method for clinical monitoring of intracranial diseases based on electromagnetic field biodetection technology according to claim 1, characterized in that: The electrode pads are brain detection sensors.

4. The method for clinical monitoring of intracranial diseases based on electromagnetic field biodetection technology according to claim 1, characterized in that: The monitor used is a non-invasive dynamic monitor for cerebral edema.

5. The method for clinical monitoring of intracranial diseases based on electromagnetic field biodetection technology according to claim 1, characterized in that: The calculation module calculates edema, hematoma, and fluid accumulation based on the detection parameters.